<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="preparation" /><meta name="keywords" content="Darbepoetin; Aranesp preparations" /><meta name="IX" content="Darbepoetin; Aranesp preparations" /><title>Aranesp®: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="106108.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="106108.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=106108.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2076.htm">9 Nutrition and blood</a> &gt; <a href="4843.htm">9.1 Anaemias and some other blood disorders</a> &gt; <a href="4910.htm">9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</a> &gt; <a href="4915.htm">Erythropoietins</a> &gt; <a href="106107.htm">DARBEPOETIN ALFA</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="4915.htm" title="Previous: Erythropoietins">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="4916.htm" title="Next: EPOETIN ALFA, BETA, THETA, and ZETA">Next page</a> ►</div></div></div></div><div id="p1"><div id="sideBar"><h2>See Also</h2><ul><li><h3>AHFS Drug Information</h3></li><li><a href="http://www.medicinescomplete.com/mc/ahfs/2010/a301064.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>AHFS Drug Information</strong> &gt; Blood Formation, Coagulation, and Thrombosis 20:00 &gt; Hematopoietic Agents 20:16</p></div></li></ul><ul><li><h3>Stockley's Interaction Alerts</h3></li><li><a href="http://www.medicinescomplete.com/mc/alerts/2010/22839-k.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin</a><div class="breadcrumb"><p><strong>Stockley's Interaction Alerts</strong> &gt; Interactants: D &gt; Interactions of Darbepoetin</p></div></li></ul><ul><li><h3>British National Formulary (2)</h3></li><li><a href="4915.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</p></div></li><li><a href="106107.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DARBEPOETIN ALFA</a><div class="breadcrumb"><p><strong>British National Formulary</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins</p></div></li></ul><ul><li><h3>BNF for Children (3)</h3></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/4915.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Erythropoietins</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/106107.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">DARBEPOETIN ALFA</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins</p></div></li><li><a href="http://www.medicinescomplete.com/mc/bnfc/2011/106108.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Aranesp®</a><div class="breadcrumb"><p><strong>BNF for Children</strong> &gt; 9 Nutrition and blood &gt; 9.1 Anaemias and some other blood disorders &gt; 9.1.3 Drugs used in hypoplastic, haemolytic, and renal anaemias &gt; Erythropoietins &gt; DARBEPOETIN ALFA</p></div></li></ul><ul><li><h3>Martindale: The Complete Drug Reference</h3></li><li><a href="http://www.medicinescomplete.com/mc/martindale/2009/20270-f.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>Martindale: The Complete Drug Reference</strong> &gt; Drugs and Ancillary Substances &gt; By therapeutic use &gt; Blood Products Plasma Expanders and Haemostatics &gt; Drug Monographs</p></div></li></ul><ul><li><h3>The Merck Index</h3></li><li><a href="http://www.medicinescomplete.com/mc/merck/2010/02824.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Darbepoetin Alfa</a><div class="breadcrumb"><p><strong>The Merck Index</strong> &gt; Monographs &gt; D &gt; DA</p></div></li></ul><ul><li><h3>Stockley's Drug Interactions</h3></li><li><a href="http://www.medicinescomplete.com/mc/stockley/2010/int-E0E0E4E3E0R0D1696.htm" onclick="pageTracker._trackEvent('Related-Topic','Related-Click');">Interactions of Darbepoetin alfa</a><div class="breadcrumb"><p><strong>Stockley's Drug Interactions</strong> &gt; Interactants, Alphabetically &gt; D</p></div></li></ul><script type="text/javascript" src="scripts/sidebar.js"></script></div><div id="pB"><h1 id="_106107">DARBEPOETIN ALFA</h1><div id="pC" class="jN"><div class="cAF"><h2>Indications</h2> <p class="cAF"> see under Dose below</p></div><div class="cAF"><h2>Cautions</h2> <p class="cAF">see <a title="target-text: Epoetin alfa and beta cautions " href="4916.htm#_4916.1">Epoetin</a></p></div><div class="cAF"><h2>Contra-indications</h2> <p class="cAF">see <a title="target-text: Epoetin alfa and beta contra-indications" href="4916.htm#_4916.3">Epoetin</a></p></div><div class="cAF"><h2>Hepatic impairment</h2> <p class="cAF">manufacturer advises caution</p></div><div class="cAF"><h2>Pregnancy</h2> <p class="cAF">no evidence of harm in <i>animal</i> studies—manufacturer
advises caution </p></div><div class="cAF"><h2>Breast-feeding</h2> <p class="cAF">manufacturer advises avoid—no information available</p></div><div class="cAF"><h2>Side-effects</h2> <p class="cAF">see <a title="target-block: Epoetin alfa and beta side-effects" href="4916.htm#_201269">Epoetin</a>; also, oedema,
injection-site pain; isolated reports of pure red cell aplasia, particularly
following subcutaneous administration in patients with chronic renal
failure (discontinue therapy)—see also <a title="target-block: Erythropoietin CSM advice" href="4915.htm#_4915.2">notes above</a></p></div><div class="cAF"><h2>Dose</h2> <p class="cR">Symptomatic anaemia associated with chronic renal failure
in patients on dialysis (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="4915.htm#_200198">MHRA/CHM advice</a>), <span class="cAK">adult</span> and <span class="cAK">child</span> over
11 years, <span class="cU">by subcutaneous</span><i> or </i><span class="cU">intravenous injection</span>, initially 450 nanograms/kg once weekly,
adjusted according to response by approx. 25% at intervals of at least
4 weeks; maintenance dose, given once weekly <i>or</i> once
every 2 weeks</p></div><div class="cAF"><p class="cR">Symptomatic anaemia associated with chronic renal failure
in patients not on dialysis (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="4915.htm#_200198">MHRA/CHM advice</a>), <span class="cAK">adult</span> and <span class="cAK">child</span> over
11 years, <span class="cU">by subcutaneous</span><i> or </i><span class="cU">intravenous injection</span>, initially 450 nanograms/kg once weekly <i>or </i><span class="cU">by subcutaneous injection</span>, initially 750 nanograms/kg
once every 2 weeks; adjusted according to response by approx. 25%
at intervals of at least 4 weeks; maintenance dose, given <span class="cU">subcutaneously</span> or <span class="cU">intravenously</span> once weekly <i>or</i> <span class="cU">subcutaneously</span> once every 2 weeks <i>or</i> <span class="cU">subcutaneously</span> once every month</p><div class="cAR"><h3>Note</h3> <p class="cAX">Subcutaneous route preferred in patients
not on haemodialysis. Reduce dose by approximately 25% if rise in
haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if haemoglobin
concentration exceeds 12 g/100 mL; if haemoglobin concentration continues
to rise, despite dose reduction, suspend treatment until haemoglobin
concentration decreases and then restart at a dose approximately 25%
lower than the previous dose. When changing route give same dose then
adjust according to weekly or fortnightly haemoglobin measurements.
Adjust doses not more frequently than every 2 weeks during maintenance
treatment</p></div></div><div class="cAF"><p class="cR">Symptomatic anaemia in adults with non-myeloid malignancies
receiving chemotherapy (see also <a title="target-block: Erythropoietins MHRA/CHM advice (target haemoglobin concentration)" href="4915.htm#_200198">MHRA/CHM advice</a>), <span class="cU">by subcutaneous injection</span>, initially 6.75 micrograms/kg once
every 3 weeks <i>or</i> 2.25 micrograms/kg once weekly (if
response inadequate after 9 weeks further treatment may not be effective);
if adequate response obtained, reduce dose by 25–50%</p><div class="cAR"><h3>Note</h3> <p class="cAX">Reduce dose by approximately 25–50% if rise
in haemoglobin concentration exceeds 2 g/100 mL over 4 weeks or if
haemoglobin concentration exceeds 12 g/100 mL; if haemoglobin concentration
continues to rise, despite dose reduction, suspend treatment until
haemoglobin concentration decreases and restart at a dose approximately
25% lower than the previous dose. Discontinue approximately 4 weeks
after ending chemotherapy</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li class="jN" id="_106108" style="margin: 0 0 0 20px;"><h1 class="title">Aranesp®<span> (<a href="appendix-112803-A.htm#m7">Amgen</a>)</span> <img class="cJ" src="images/pom_l.png" title="Prescription-only Medicine" alt="Prescription-only Medicine" /></h1><div class="cAY"><span class="cAB">Injection</span>, prefilled syringe, darbepoetin alfa, 25 micrograms/mL,
net price 0.4 mL (10 micrograms) = £14.68; 40 micrograms/mL, 0.375 mL
(15 micrograms) = £22.03, 0.5 mL (20 micrograms) = £29.37; 100 micrograms/mL,
0.3 mL (30 micrograms) = £44.05, 0.4 mL (40 micrograms) = £58.73,
0.5 mL (50 micrograms) = £73.41; 200 micrograms/mL, 0.3 mL (60 micrograms)
= £88.09, 0.4 mL (80 micrograms) = £117.45, 0.5 mL (100 micrograms)
= £146.81, 0.65 mL (130 micrograms) = £190.86; 500 micrograms/mL,
0.3 mL (150 micrograms) = £220.22, 0.6 mL (300 micrograms) = £440.43,
1 mL (500 micrograms) = £734.05</div><div class="cAY"><span class="cAB">Injection</span> (<span class="cZ">Aranesp®SureClick</span>), prefilled disposable injection device, darbepoetin alfa, 40 micrograms/mL,
net price 0.5 mL (20 micrograms) = £29.36; 100 micrograms/mL, 0.4 mL
(40 micrograms) = £58.72; 200 micrograms/mL, 0.3 mL (60 micrograms)
= £88.09, 0.4 mL (80 micrograms) = £117.45, 0.5 mL (100 micrograms)
= £146.81; 500 micrograms/mL, 0.3 mL (150 micrograms) = £220.22, 0.6 mL
(300 micrograms) = £440.43, 1 mL (500 micrograms) = £734.05</div></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="4915.htm">Previous: Erythropoietins</a> | <a class="top" href="106108.htm#">Top</a> | <a accesskey="]" href="4916.htm">Next: EPOETIN ALFA, BETA, THETA, and ZETA</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>